Table 1.
Patients’ characteristics and their effects on NODM
| Characteristics | Non-NODM | NODM | Univariate | Multivariate | ||
|---|---|---|---|---|---|---|
| N (%) or mean ± SD | N (%) or mean ± SD | OR (95% CI) | P value | OR (95% CI) | P value | |
| Demographic data | ||||||
| Total no. | 605 | 99 | ||||
| Age | 61.8 ± 10.8 | 1.03 (1.01–1.05) | 0.002 | |||
| Gender | ||||||
| Female | 153 (25.3%) | 36 (36.4%) | ||||
| Male | 452 (74.7%) | 63 (63.6%) | 0.59 (0.38–0.93) | 0.022 | ||
| Dosage (mg) | ||||||
| 5 | 14 (2.3%) | 2 (2%) | ||||
| 10 | 534 (88.3%) | 85 (85.9%) | ||||
| 20 | 57 (9.4%) | 12 (12.1%) | 1.03 (0.96–1.10) | 0.398 | ||
| Medical history | ||||||
| Arrhythmia | ||||||
| No | 565 (93.4%) | 90 (90.9%) | ||||
| Yes | 40 (6.6%) | 9 (9.1%) | 1.41 (0.66–3.01) | 0.371 | ||
| Heart failure | ||||||
| No | 587 (97%) | 85 (85.9%) | ||||
| Yes | 18 (3%) | 14 (14.1%) | 5.37 (2.58–11.20) | 0.001 | 4.83 (2.25–10.35) | 0.000 |
| Hypertension | ||||||
| No | 353 (58.3%) | 51 (51.5%) | ||||
| Yes | 252 (41.7%) | 48 (48.5%) | 1.32 (0.86–2.02) | 0.203 | ||
| Hyperlipidemia | ||||||
| No | 552 (91.2%) | 93 (93.9%) | ||||
| Yes | 53 (8.8%) | 6 (6.1%) | 0.67 (0.28–1.61) | 0.372 | ||
| Biochemical measurements | ||||||
| ALT, U/L | 31.0 ± 26.8 | 34.4 ± 25.1 | 1.00 (1.00–1.01) | 0.240 | ||
| AST, U/L | 30.4 ± 23.4 | 34.8 ± 37.1 | 1.01 (1.00–1.01) | 0.128 | ||
| CREA, μmol/L | 83.0 ± 33.0 | 89.1 ± 44.6 | 1.00 (1.00–1.01) | 0.113 | ||
| CK, U/L | 116.1 ± 140.6 | 141.5 ± 362.4 | 1.00 (1.00–1.00 | 0.247 | ||
| APOA, g/L | 1.1 ± 0.3 | 1.1 ± 0.3 | 1.03 (0.48–2.18) | 0.942 | ||
| TC, mmol/L | 4.4 ± 1.2 | 4.4 ± 1.3 | 0.98 (0.83–1.17) | 0.861 | ||
| CKMB, U/L | 7.2 ± 5.6 | 8.3 ± 12.0 | 1.02 (0.99–1.04) | 0.166 | ||
| HDL-C, mmol/L | 1.0 ± 0.3 | 1.0 ± 0.3 | 0.68 (0.29–1.56) | 0.360 | ||
| LDL-C, mmol/L | 2.7 ± 1.0 | 2.6 ± 0.8 | 0.89 (0.71–1.12) | 0.334 | ||
| Lpa, mg/L | 273.4 ± 301.0 | 304.4 ± 330.2 | 1.00 (1.00–1.00) | 0.350 | ||
| TG, mmol/L | 1.5 ± 1.0 | 1.8 ± 1.8 | 1.17 (1.00–1.36) | 0.047 | 1.24 (1.05–1.47) | 0.013 |
| Plasma exposure | ||||||
| RST, ng/ML | 3.8 ± 3.4 | 5.4 ± 4.6 | 1.53 (1.17–1.99) | 0.002 | 1.47 (1.12–1.93) | 0.005 |
| RSTL, ng/ML | 0.5 ± 0.5 | 0.7 ± 0.7 | 1.32 (1.05–1.65) | 0.018 | ||
| Medication | ||||||
| β-Blockers | ||||||
| No | 98 (16.2%) | 13 (13.1%) | ||||
| Yes | 507 (83.8%) | 86 (86.9%) | 1.28 (0.69–2.38) | 0.438 | ||
| ACEIs | ||||||
| No | 298 (49.3%) | 50 (50.5%) | ||||
| Yes | 307 (50.7%) | 49 (49.5%) | 0.95 (0.62–1.46) | 0.818 | ||
| CCBs | ||||||
| No | 447 (73.9%) | 64 (64.6%) | ||||
| Yes | 158 (26.1%) | 35 (35.4%) | 1.55 (0.99–2.43) | 0.057 | ||
| PPIs | ||||||
| No | 304 (50.2%) | 39 (39.4%) | ||||
| Yes | 301 (49.8%) | 60 (60.6%) | 1.55 (1.01–2.40) | 0.046 | ||
| Clop | ||||||
| No | 21 (3.5%) | 3 (3%) | ||||
| Yes | 584 (96.5%) | 96 (97%) | 1.15 (0.34–3.93) | 0.823 | ||
| Aspirin | ||||||
| No | 31 (5.1%) | 5 (5.1%) | ||||
| Yes | 574 (94.9%) | 94 (94.9%) | 1.02 (0.39–2.68) | 0.976 | ||
ALT, alanine transaminase; AST, aspartate transaminase; CREA, creatinine; CK, Creatine Kinase; APOA, apolipoprotein a; TC, total cholesterol; CKMB, creatine kinase-MB; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; Lpa, lipoprotein (a); TG, triglycerides; RST, rosuvastatin; RSTL, rosuvastatin lactone; β-blockers, beta-blockers; ACEIs, angiotensin converting enzyme inhibitors; CCBs, calcium channel blockers; PPIs, proton pump inhibitors; clop, clopidogrel
Variables with p < 0.1 were entered into the multivariable model, and only variables with p < 0.05 were retained in the model